Intensifying Competition from Multi-Injection Products and Hyaluronic Acid APIs
First written in FY2017-Q2. 7 of 23 entries say "Restated". Latest entry: 2026-08-05.
Seikagaku moved to the "Worse" side of this theme in 2017, 5 years before the typical company in this theme (2022).
The whole theme swung hardest in 2025: 4 of 8 companies on the "Worse" side.
4 other companies' latest entry also says "Worsened".
- 2026-08-05WorsenedEarnings
「In the U.S. market for joint-function improvement agents, one of our core markets, the number of patients is trending upward, but intensified price competition has limited market expansion in value terms.」
The company added that intensified price competition has limited market expansion in value terms in the U.S. market for joint-function improvement agents. - FY2026Specific Drivers of the Decline in Supartz FX IdentifiedAnnual report
「The decline in SUPARTZ FX, a 5-dose formulation, is believed to have been affected by the shift in the U.S. joint-function improvement product market toward products administered fewer times, 1 to 3 doses, in addition to shipment timing.」
The view was expressed that the decline in SUPARTZ FX was affected by shipment timing and the shift in the U.S. market toward products administered 1 to 3 doses. - FY2025Local sales volumes flat, sales increased due to inventory adjustmentsAnnual report
「For SUPARTZ FX in the United States, local sales volumes were broadly unchanged from the previous fiscal year, but our sales increased due to inventory adjustments by our sales partner.」
Although the market environment remained challenging for multi-dose products, SUPARTZ FX's local sales volumes were broadly unchanged from the previous fiscal year, while our sales increased due to inventory adjustments by our partner. - FY2024-Q3RestatedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes increase due to changes in the market environment following changes to the reimbursement system. Our sales increased due to adjustments to shipment timing and the weaker yen.」
Although the market environment remained challenging for multi-dose products, changes in the market environment following changes to the reimbursement system led to increases in SUPARTZ FX's local sales volumes and our sales. - FY2024-Q1Sales increased in the market environment following changes to the reimbursement systemAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes increase due to changes in the market environment following changes to the reimbursement system. Our sales increased due to adjustments to shipment timing and the weaker yen.」
Although the preference for products administered fewer times continued to make the environment challenging for multi-dose products, changes in the market environment following changes to the reimbursement system led to increases in SUPARTZ FX's local sales volumes and our sales. - FY2023-Q3Local sales volumes up slightly, sales broadly unchanged from the same period of the previous yearAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, continued to face a challenging environment due to the preference for products administered fewer times, but local sales volumes increased slightly. Our sales were broadly unchanged from the same period of the previous year due to the impact of shipment timing, despite the positive effect of the weaker yen.」
Although the preference for products administered fewer times continued to make the environment challenging for multi-dose products, SUPARTZ FX's local sales volumes increased slightly. Our sales were broadly unchanged from the same period of the previous year due to the impact of shipment timing. - FY2023-Q2RestatedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, continued to face a challenging environment for multi-dose products due to the preference for products administered fewer times, but local sales volumes were broadly unchanged from the same period of the previous year. Our sales declined due to shipment timing.」
The preference for products administered fewer times has continued to make the environment challenging for multi-dose products. SUPARTZ FX's local sales volumes were broadly unchanged from the same period of the previous year, while our sales declined due to shipment timing. - FY2022-Q2RestatedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes increase on the rebound from the significant impact of the spread of COVID-19 in the same period of the previous year, despite the continued preference for products administered fewer times such as single-dose and 3-dose products.」
Although the competitive environment favoring products administered fewer times continued, SUPARTZ FX's local sales volumes increased on the rebound from the impact of the pandemic in the same period of the previous year. - FY2022-Q1Sales increased on the rebound from the impact of the pandemic in the previous year, despite continued preference for products administered fewer timesAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes and our sales increase because the spread of COVID-19 had had a significant impact in the same period of the previous year, despite the continued preference for products administered fewer times.」
Although the competitive environment favoring products administered fewer times continued, SUPARTZ FX's local sales volumes and our sales increased on the rebound from the impact of the pandemic in the same period of the previous year. - FY2021-Q3WorsenedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes and our sales decline due to the continued preference for products administered fewer times, as well as a decline in outpatient visits.」
SUPARTZ FX continued to see declines in local sales volumes and our sales due to the preference for products administered fewer times and the impact of fewer outpatient visits accompanying the spread of COVID-19. - FY2021-Q1WorsenedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes and our sales decline due to the continued preference for products administered fewer times and the impact of COVID-19.」
SUPARTZ FX continued to see declines in local sales volumes and our sales due to the preference for products administered fewer times, in addition to the impact of the pandemic. - FY2020-Q3RestatedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes and our sales decline due to the continued U.S. preference for products administered fewer times.」
The continued U.S. preference for products administered fewer times has led to ongoing declines in SUPARTZ FX's local sales volumes and sales. - FY2020-Q2RestatedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes decline due to the continued U.S. preference for products administered fewer times, such as single-dose and 3-dose products. However, our sales increased due to higher advance shipments.」
The preference for products administered fewer times continued, and SUPARTZ FX's local sales volumes declined. However, our sales increased due to advance shipments. - FY2020-Q1RestatedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales volumes and our sales decline as U.S. preferences continued to shift toward products administered fewer times, such as single-dose and 3-dose products.」
The continued U.S. preference for products administered fewer times has continued to affect results through declines in SUPARTZ FX's local sales volumes and our sales. - FY2019WorsenedAnnual report
「The U.S. hyaluronic acid injection market began to contract in value terms due to the impact of intensifying competition and the suspension of reimbursement by some insurers, among other factors. SUPARTZ FX, a joint-function improvement product administered in 5 doses, was significantly affected by the suspension of reimbursement, and both local sales and our sales declined substantially.」
In addition to intensifying competition, insurers suspended reimbursement, causing the U.S. market to begin contracting in value terms. The impact intensified in the form of substantial declines in SUPARTZ FX's local sales and our sales. - FY2019-Q3WorsenedAnnual report
「In the U.S. hyaluronic acid injection market, the environment became increasingly challenging due to intensifying competition and tighter reimbursement policies, and the impact was reflected in a substantial decline in SUPARTZ FX's local sales and our sales. SUPARTZ FX, a joint-function improvement product administered in 5 doses, was significantly affected by the tighter reimbursement policies.」
In the U.S. hyaluronic acid injection market, intensifying competition and tighter reimbursement policies made the environment increasingly challenging, with the impact appearing as a substantial decline in SUPARTZ FX's local sales and our sales. - FY2019-Q2WorsenedAnnual report
「In the United States, the market environment for hyaluronic acid injections is becoming increasingly challenging due to intensifying competition and tighter reimbursement policies by some insurers, among other factors.」
The disclosure states that the U.S. hyaluronic acid injection market became more challenging due to intensifying competition and tighter reimbursement policies by insurers. - FY2019-Q1WorsenedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local sales decline as U.S. preferences increasingly shifted toward products administered fewer times, such as 3-dose and single-dose products.」
The preference for products administered fewer times strengthened, causing SUPARTZ FX's local U.S. sales to decline. The competitive environment for multi-dose products is becoming increasingly challenging. - FY2018-Q3RestatedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local U.S. sales decline slightly as the competitive environment became more challenging, but our sales increased due to higher local inventories held by our sales partner.」
While competition among multi-dose products intensified and SUPARTZ FX's local sales continued to decline slightly, our sales increased due to higher inventories held locally by our sales partner. - FY2018-Q1MaterialisedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local U.S. sales decline slightly as the competitive environment became more challenging.」
Continued intensifying competition among multi-dose products has appeared in results as a slight decline in SUPARTZ FX's local U.S. sales. - FY2017MaterialisedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw local U.S. sales decline slightly as the competitive environment became more challenging, including with the addition of new multi-dose products.」
Continued intensifying competition among multi-dose products has appeared in full-year results as a slight decline in SUPARTZ FX's local U.S. sales. - FY2017-Q3MaterialisedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw a slight decline in local U.S. sales as the competitive environment for multi-dose products remained challenging.」
Intensifying competition among multi-dose products continued to be reflected in results as a slight decline in SUPARTZ FX's local U.S. sales. - FY2017-Q2First statedAnnual report
「SUPARTZ FX, a joint-function improvement product administered in 5 doses, saw a slight decline in local U.S. sales as the competitive environment for multi-dose products remained challenging. Sales of hyaluronic acid active pharmaceutical ingredients declined due to intense competition.」
Intensifying competition among multi-dose products has appeared as a slight decline in SUPARTZ FX's local U.S. sales, while intensified competition for hyaluronic acid has appeared as a decline in sales of pharmaceutical active ingredients.